TY - JOUR
T1 - National survey of pharmacists about coronary heart disease, hypercholesterolemia, nonprescription statin therapy, and pharmacists' services
AU - McKenney, James M.
AU - Chris Bradberry, J.
AU - Talbert, Robert L.
AU - Cahill, Edward
AU - Virgil Brown, W.
N1 - Funding Information:
Funding: Supported in part by an unrestricted educational grant from J&J Merck.
PY - 2004
Y1 - 2004
N2 - Objective: To determine the beliefs and attitudes of pharmacists about the significance of high blood cholesterol, coronary heart disease (CHD), nonprescription statin therapy for patients at moderate risk for CHD, and their role in support of cholesterol-lowering treatments in patients. Design: Cross-sectional survey. Setting: Nationwide sample of licensed pharmacists in ambulatory practice in the United States drawn randomly from databases of the American Pharmacists Association. Participants: 104 independent pharmacists and 169 chain pharmacists. Intervention: Web-based survey. Main Outcome Measure: Respondents' indication of strong agreement with questionnaire statements (selecting 8, 9, or 10 on a 10-point scale). Results: The survey found that 75% and 61% of pharmacists believed strongly that CHD and high blood cholesterol levels, respectively, are significant health problems facing Americans, and 60% believed that not enough is currently being done to reduce this risk. Pharmacists indicated that they very regularly advised patients about prescription and nonprescription treatments (75%) and encouraged adherence to them (78%); a smaller but substantial proportion regularly monitored patient response to prescription (33%) and nonprescription therapies (15%) and provided point-of-care cholesterol testing (7%). The survey also revealed that the majority of pharmacists (68%) would support consumers interested in purchasing a nonprescription statin product and 82% believed such a product would be more effective than currently available cholesterol-lowering dietary supplements. Pharmacists were concerned that patients pursuing nonprescription statins might discontinue their prescription cholesterol-lowering medications (79%), experience adverse effects (79%), and not be able to self-manage their use of a nonprescription statin product (78%). Conclusion: Community pharmacist members of APhA believe that CHD and cholesterol are important problems facing many people, routinely provide services that support patients who wish to self-administer nonprescription therapies, and would be interested in supporting consumers who wish to carry out therapy with a nonprescription statin.
AB - Objective: To determine the beliefs and attitudes of pharmacists about the significance of high blood cholesterol, coronary heart disease (CHD), nonprescription statin therapy for patients at moderate risk for CHD, and their role in support of cholesterol-lowering treatments in patients. Design: Cross-sectional survey. Setting: Nationwide sample of licensed pharmacists in ambulatory practice in the United States drawn randomly from databases of the American Pharmacists Association. Participants: 104 independent pharmacists and 169 chain pharmacists. Intervention: Web-based survey. Main Outcome Measure: Respondents' indication of strong agreement with questionnaire statements (selecting 8, 9, or 10 on a 10-point scale). Results: The survey found that 75% and 61% of pharmacists believed strongly that CHD and high blood cholesterol levels, respectively, are significant health problems facing Americans, and 60% believed that not enough is currently being done to reduce this risk. Pharmacists indicated that they very regularly advised patients about prescription and nonprescription treatments (75%) and encouraged adherence to them (78%); a smaller but substantial proportion regularly monitored patient response to prescription (33%) and nonprescription therapies (15%) and provided point-of-care cholesterol testing (7%). The survey also revealed that the majority of pharmacists (68%) would support consumers interested in purchasing a nonprescription statin product and 82% believed such a product would be more effective than currently available cholesterol-lowering dietary supplements. Pharmacists were concerned that patients pursuing nonprescription statins might discontinue their prescription cholesterol-lowering medications (79%), experience adverse effects (79%), and not be able to self-manage their use of a nonprescription statin product (78%). Conclusion: Community pharmacist members of APhA believe that CHD and cholesterol are important problems facing many people, routinely provide services that support patients who wish to self-administer nonprescription therapies, and would be interested in supporting consumers who wish to carry out therapy with a nonprescription statin.
KW - Hypercholesterolemia
KW - Lipids
KW - Nonprescription medications
KW - Pharmaceutical care, pharmacists' opinions
KW - Self-care
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=85047688410&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047688410&partnerID=8YFLogxK
U2 - 10.1331/1544-3191.44.5.562.McKenney
DO - 10.1331/1544-3191.44.5.562.McKenney
M3 - Article
C2 - 15496041
AN - SCOPUS:85047688410
VL - 44
SP - 562
EP - 568
JO - Journal of the American Pharmaceutical Association. American Pharmaceutical Association
JF - Journal of the American Pharmaceutical Association. American Pharmaceutical Association
SN - 1544-3191
IS - 5
ER -